author-photo

Hanna A. Knaus

Johns Hopkins University

14

Papers

162

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

2021
Show All
- Source
- Cite
- Save
Citations (2)
Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (7)
A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Signatures of CD8 + T cell dysfunction in AML patients and their reversibility with response to chemotherapy

2018 JCI insight
Show All
- Source
- Cite
- Save
Citations (69)
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

2018 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (41)
A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMAS) Failure

2017 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (0)
Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial

2015 Blood
Show All
- Source
- Cite
- Save
Citations (10)